A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2019
Price : $35 *
At a glance
- Drugs Mometasone (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Sponsors Lyra Therapeutics
- 31 Jul 2019 Status changed from planning to recruiting.
- 08 Oct 2018 According to a Lyra Therapeutics media release, this trial is expected to begin in the first half of 2019.
- 05 Oct 2018 New trial record